Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion.
R M Durham, A J Lechner, C A Johanns, Z Chen, G M Matuschak
Index: J. Surg. Res. 76(2) , 179-84, (1998)
Full Text: HTML
Abstract
Muramlytripeptide phosphatidylethanolamine (MTP) stimulates synthesis of cytokines by hepatic Kupffer cells. We have shown in a perfused rat liver model that secondary ischemia/reperfusion (I/R) downregulates tumor necrosis factor alpha (TNF-alpha) expression after Escherichia coli (EC) bacteremia. Here, we tested the hypothesis that pretreatment with MTP restores cytokine response after sequential bacteremia and I/R.Thirty-eight livers were studied in eight groups after intraportal injection of 10(9) live EC or normal saline (NS): (1) normoxic EC; (2) EC + I/R (ischemia began 30 min after EC followed by 2 h of reperfusion); (3) normoxic NS controls; and (4) NS + I/R. Four groups of rats received 300 micrograms of MTP i.v. 24 h prior to liver harvesting; (5) MTP + EC; (6) MTP + EC + I/R; (7) MTP + NS; and (8) MTP + NS + I/R. Bioactive and antigenic TNF-alpha, PGE2 and bacterial clearance were assessed.MTP increased bioactive TNF-alpha response to EC (MTP + EC vs EC controls: 685 +/- 255 U/ml vs 250 +/- 180 U/ml, P < 0.02). I/R did not downregulate TNF-alpha in animals treated with MTP (MTP + NS vs MTP + NS +I/R, P = 0.83). Pretreatment with MTP restored TNF-alpha after I/R MTP + EC + I/R vs EC + I/R: 671 +/- 215 U/ml vs 27 +/- 14 U/ml, P < 0.001) to levels similar to those found in the MTP + EC group (MTP + EC + I/R vs MTP + EC: 671 +/- 215 U/ml vs 685 +/- 255 U/ml, P = 0.75). Finally, bacterial clearance was increased in groups which received MTP.In vivo administration of MTP increases hepatic TNF-alpha response to intraportal EC bacteremia by a PGE2 independent mechanism. This response is maintained even after subsequent ischemia and reperfusion.
Related Compounds
Related Articles:
2009-08-01
[Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)]
2008-09-01
[Parasitol. Res. 103(4) , 919-29, (2008)]
1999-04-01
[Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)]
1998-10-01
[Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)]
2008-02-01
[Expert Rev. Anticancer Ther. 8(2) , 151-9, (2008)]